Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg. Gilead had the right to ...
HAYWARD, Calif., February 18, 2025--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and ...
The company’s pipeline of products based on allogeneic chimeric antigen receptor (CAR)-T cells are engineered ex vivo using the ARCUS platform to optimize donor cells and thereby improve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback